Gout (Podiatric).Care & specialists in South Africa

Gout is not curable in the sense that the underlying hyperuricemia tendency persists, but it is fully controllable. With urate-lowering therapy held below 6.0 mg/dL, monosodium urate crystals dissolve, flares stop recurring (typically within 6-12 months), and tophi shrink over 1-3 years. Most well-treated patients remain flare-free for years and live a normal life. The treatment is lifelong, similar to how high blood pressure is managed.

The classic gout presentation is sudden severe pain in a single joint — most often the base of the big toe — that peaks within 12-24 hours, is bright red and warm, and resolves over 1-2 weeks. Definitive diagnosis requires joint aspiration to look for uric acid crystals under polarized microscopy. A blood test for uric acid supports the diagnosis but can be misleadingly normal during an attack. See a clinician promptly for any acutely hot, red, swollen joint to rule out infection.

Most patients describe a gout flare as the worst pain they have experienced — sudden, intense, throbbing, with the joint so tender that even a bedsheet is unbearable. Onset is typically overnight, the joint becomes visibly red and swollen within hours, and weight-bearing on an affected big toe is impossible. The pain peaks at 12-24 hours and gradually settles over 1-2 weeks if untreated.

Common triggers include a heavy meal of red meat, organ meat, or seafood; binge alcohol consumption (especially beer); dehydration; sudden weight loss or fasting; starting or stopping urate-lowering therapy; thiazide diuretics; trauma to a joint; and intercurrent illness or surgery. The shared mechanism is a rapid shift in serum urate concentration, which destabilizes crystal deposits.

The first metatarsophalangeal joint runs slightly cooler than core body temperature and bears mechanical stress with every step. Both factors lower the solubility of uric acid in that joint, making it the first site where crystals reach the saturation point and trigger inflammation. About 50% of first attacks involve this joint, a presentation called podagra.

Untreated, a gout flare typically resolves over 7-14 days. With anti-inflammatory treatment (NSAIDs, colchicine, or steroids) started within the first 24 hours, pain drops by half within 1-2 days and resolves over 5-7 days. The faster treatment starts, the shorter and milder the flare.

Diet changes can lower serum uric acid by approximately 0.5-1.0 mg/dL — meaningful but usually not enough on its own once gout is established. Patients with infrequent mild flares can sometimes manage with dietary changes plus weight loss. Once flares recur or tophi appear, urate-lowering medication is the only reliable way to keep urate below the crystallization threshold long-term.

Yes, allopurinol is well-tolerated by most patients and is safe for lifelong use when serum urate, renal function, and liver function are monitored. The main risk is a severe skin reaction (Stevens-Johnson syndrome or DRESS) which occurs in roughly 1 in 1,000 starters and is strongly linked to the HLA-B*5801 gene variant — common in Han Chinese, Thai, and Korean populations. Screening before starting is recommended in those groups. Once a patient tolerates allopurinol for the first 8 weeks, the long-term safety profile is excellent.

If urate-lowering therapy is indicated (recurrent flares, tophi, CKD, or kidney stones), the recommendation is lifelong. The underlying tendency to high urate does not go away, and stopping medication after a few years almost always leads to flares within 12 months. Treatment is similar in pattern to managing high blood pressure or high cholesterol.

Beer and spirits should be limited or avoided — both raise serum urate and trigger flares. Wine in moderation has a much smaller effect; up to one glass daily appears acceptable for most stable patients on urate-lowering therapy. Total abstinence is rarely necessary, but binge drinking is a reliable flare trigger and should be avoided.

Yes. Premenopausal women have lower urate due to the uricosuric effect of estrogen, so gout is uncommon before menopause. After menopause, women's gout risk approaches that of men, and within 10 years of menopause prevalence is similar. Postmenopausal gout often presents in the hands rather than the feet and can be mistaken for osteoarthritis.

Gout is caused by monosodium urate crystals, most often affects the big toe, and presents with very high serum urate. Pseudogout (calcium pyrophosphate deposition disease) is caused by a different crystal — calcium pyrophosphate — usually involves the knee or wrist, and occurs in older adults with normal urate. Both are confirmed by joint aspiration, but the crystal shape and birefringence under polarized light differ.

Yes — uric acid kidney stones occur in 20-25% of patients with long-standing gout. Both conditions share hyperuricemia as the root cause. Adequate hydration, urinary alkalinization, and the same urate-lowering medications used for gout substantially reduce stone recurrence.

Untreated chronic gout does cause permanent joint erosion and deformity, visible on X-rays after 10-20 years of disease. With urate-lowering therapy maintained below 6.0 mg/dL, this progression stops and tophi shrink, though existing erosions and deformity do not reverse. Early treatment preserves joint structure.

A tophus is a firm, painless, chalky-white deposit of monosodium urate crystals embedded in soft tissue — usually over a joint, the ear helix, the Achilles tendon, or the back of the elbow. Tophi develop after years of uncontrolled hyperuricemia and indicate a high body burden of crystals. They shrink slowly with urate-lowering therapy held below 5.0 mg/dL.

Acute flare treatments (NSAIDs, colchicine, prednisolone) are inexpensive generic drugs available worldwide. Allopurinol, the mainstay of long-term therapy, costs roughly USD 5-15 per month in most countries as a generic. Specialist visits, joint aspirations, and uncommon medications (febuxostat, pegloticase) add cost — pegloticase in particular runs into thousands of dollars per dose. In India and other emerging markets, allopurinol generics are widely affordable.

Avoid weight-bearing exercise on the affected joint during an acute flare — rest, elevation, and ice are the immediate measures. Once swelling and pain settle (usually 5-7 days with treatment), gradually return to normal activity. Between flares, regular low-impact exercise such as swimming, cycling, or walking is encouraged and helps with weight management and overall metabolic health.

There is a strong genetic component — heritability is estimated at 45-73% from twin studies. Variants in genes that control uric acid transport in the kidney (SLC2A9, ABCG2, SLC22A11, SLC22A12) explain most of the familial risk. A first-degree relative with gout increases personal risk roughly 2-3 fold. Lifestyle modifies the expression of this genetic predisposition.

See a rheumatologist if flares recur despite first-line treatment, if you cannot reach the urate target on standard allopurinol doses, if tophi or visible joint erosions develop, if you have known kidney disease or transplant medications complicating drug choice, or if there is diagnostic uncertainty between gout and other arthropathies. Most uncomplicated gout is managed effectively in primary care if treat-to-target is followed.

Starting allopurinol during or immediately after an acute flare can briefly worsen flare risk as crystals mobilize. Current guidelines (ACR 2020) allow starting during a flare if anti-inflammatory cover is in place, but many clinicians prefer to wait 2-4 weeks for symptoms to settle, then start at a low dose with prophylactic colchicine alongside. Both approaches are evidence-supported.

Psychological stress alone is not an established direct trigger, but stress-related changes — disrupted sleep, dehydration, alcohol use, missed medications, surgical stress — are well-documented precipitants. Maintaining hydration, medication adherence, and steady habits during stressful periods reduces flare risk.